Search clinical trials for: TKI 258

Total 632 results

Azienda Socio Sanitaria Territoriale degli Spedali...

Recruiting

Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

Leukemia, Chronic Myeloid

Italy
Hunan Province Tumor Hospital

Recruiting

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Carcinoma, Non-Small Cell Lung | EGFR Gene Mutation

China
Sun Yat-sen University

Recruiting

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Non-small Cell Lung Cancer (NSCLC) | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation | Somatic Mutation | Germline Mutations

China
Janssen Research & Development, LLC

Active, not recruiting

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)

Non-Small-Cell Lung Cancer

United States, France, Taiwan, United Kingdom, China, Spain, Japan, Australia, Korea, Republic of, Canada
Novartis Pharmaceuticals

Active, not recruiting

De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE)

Chronic Myeloid Leukemia

Italy
AstraZeneca

Active, not recruiting

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)

Non-Small Cell Lung Cancer

Denmark, Italy, Spain, United States, Korea, Republic of, Japan, Netherlands, Norway, Sweden
Wageningen University
Unilever R&D; Arla Foods; Bournemouth University; Cargill; TKI Agri & Food; American... and other collaborators

Completed

Sweet Tooth: Nature or Nurture? Role of Long-term Dietary Sweetness Exposure on Sweetness Preferences

Food Preferences

Netherlands
AstraZeneca

Active, not recruiting

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA)

Stage IB-IIIA Non-small Cell Lung Carcinoma

United States, Italy, Netherlands, Belgium, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Brazil, Hungary, Japan, Russian Federation, Turkey, China, Korea, Republic of, Germany, Hong Kong, Spain, Australia, Israel, Ukraine, Swed...
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
Theseus Pharmaceuticals

Terminated

A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Diseases | Neoplasms | Neoplasms, Connective and Soft Tissue | Neoplasms by Histologic Type | Gastrointestinal Neoplasms | Neoplasms, Connective Tissue | Digestive System Neoplasm | Digestive System Disease | Gastrointestinal Stromal Tumors (GIST)

United States
Akeso
Akeso Tiancheng, Inc

Completed

A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

B Acute Lymphoblastic Leukemia | Central Nervous System Leukemia | Testicular Leukemia | B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

United States, Canada, Puerto Rico, Australia, New Zealand, Switzerland, Ireland
Novartis Pharmaceuticals

Active, not recruiting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

United States, China, Hungary, Japan, Belgium, Germany, Canada, Singapore, Australia, Israel, Netherlands, Spain, Italy, Korea, Republic of, Bulgaria, France, United Kingdom, Czechia, Sweden, India, Malaysia, Denmark, Taiwan, Norway, Fi... and more
Akeso
Akeso Pharmaceuticals, Inc.

Completed

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
The First Affiliated Hospital of Soochow University

Completed

Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Philadelphia Chromosome | Mixed Phenotype Acute Leukemia

China
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Chronic Myelogenous Leukemia

United States, United Kingdom, Hungary, Japan, Saudi Arabia, Australia, Germany, Canada, France, Netherlands, Spain, Lebanon, Turkey, Korea, Republic of, Argentina, Brazil, Bulgaria, Czechia, Israel, Italy, Mexico, Romania, Russian... and more
Daiichi Sankyo

Active, not recruiting

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

EGFR L858R | EGFR Exon 19 Deletion | Nonsquamous Non-small Cell Lung Cancer

Korea, Republic of, United States, Netherlands, Spain, United Kingdom, Japan, Austria, Belgium, Italy, France, Taiwan, Germany, Australia, Singapore, China, Hong Kong, Norway, Canada, Poland, Portugal, Switzerland
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Taiwan, Serbia, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Greece, Ukraine
Bayer

Completed

A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Netherlands
H. Lee Moffitt Cancer Center and Research Institute
National Heart, Lung, and Blood Institute (NHLBI); CTI BioPharma

Completed

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

GVHD | Graft Vs Host Disease

United States
AstraZeneca

Completed

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

Belgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
Novartis Pharmaceuticals

Completed

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Germany, Australia, Netherlands, Spain, Korea, Republic of, France, Japan, Italy, Singapore, United States
Merck Sharp & Dohme LLC

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Renal Cell Carcinoma
Sun Yat-sen University
Second Affiliated Hospital of Guangzhou Medical University

Completed

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Carcinoma, Hepatocellular | Liver Neoplasms | Sintilimab | Portal Vein Tumor Thrombus

China
Pfizer

Completed

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Non-Small Cell Lung Carcinoma

Taiwan
Fudan University

Completed

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

NSCLC Stage IV | EGFR Activating Mutation

China
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread (PIVOT IO 011)

Renal Cell Carcinoma

United States, Argentina, Brazil, Canada, France, Germany, Mexico, Russian Federation
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor

Metastatic Renal Cell Carcinoma | Diarrhea | Stage IV Renal Cell Cancer

United States
European Society for Blood and Marrow Transplantation
Novartis

Completed

Effect of 2nd Gen TKI in CML

Myeloid Leukemia, Chronic

Germany, Finland, Denmark, Poland, Saudi Arabia, United Kingdom, Israel, Hungary, Russian Federation
Stanford University
National Institutes of Health (NIH)

Active, not recruiting

Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

Kidney Cancer | Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma

United States
University of Virginia

Active, not recruiting

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies (Lung001)

Lung Cancer | ALK Gene Mutation | MET Gene Mutation | KRAS Mutation-Related Tumors | RET Gene Mutation | EGFR Gene Mutation | EGFR | ROS1 Gene Mutation | BRAF

United States
National Cancer Centre, Singapore
Pfizer

Active, not recruiting

Phase 2 Study of Dacomitinib in NSCLC

NSCLC Stage IV | NSCLC Stage IIIB | Recurrent NSCLC | NSCLC Stage IIIC | EGFR Positive Non-Small Cell Lung Cancer

Korea, Republic of, Hong Kong, Thailand, Singapore, Malaysia
Ocular Therapeutix, Inc.

Completed

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Wageningen University
Mead Johnson Nutrition; Top Consortium for Knowledge and Innovation (TKI) Argi... and other collaborators

Completed

FIT to Grow Old - Functionality of the Immune System and Healthy Aging (FTGO)

Aging

Netherlands
Merck Sharp & Dohme LLC

Completed

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Non-small Cell Lung Cancer

China, Taiwan, Japan, Korea, Republic of, United States, Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Italy, Mexico, Spain, Sweden, United Kingdom
Peking University People's Hospital

Completed

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Soft Tissue Sarcoma | Bone Sarcoma | Refractory Tumor

China
The Fourth Affiliated Hospital of Zhejiang University...

Completed

Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients

NSCLC | EGFR Gene Mutation | Non-small-lung-cell Cancer

China
Fundacion CRIS de Investigación para Vencer el...
Apices Soluciones S.L.; Incyte Biosciences UK

Active, not recruiting

Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP) (ResToP)

Chronic Myeloid Leukemia, Chronic Phase

Spain
Tian Xie
LinkDoc Technology (Beijing) Co. Ltd.

Active, not recruiting

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study (SELECT-1)

Carcinoma, Non-Small-Cell Lung

China
Institute of Cancer Research, United Kingdom

Active, not recruiting

Stereotactic Body Radiotherapy for the Treatment of OPD (HALT)

NSCLC

United Kingdom, France, Switzerland, Italy, Spain
Bridge Biotherapeutics, Inc.

Terminated

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

NSCLC

Korea, Republic of
Fudan University

Completed

IASLC Grading System as a Predictor for EGFR-TKI Therapy

Lung Cancer

China
European LeukemiaNet
Ludwig-Maximilians - University of Munich; Heidelberg University

Active, not recruiting

2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (NAUT)

Chronic Myeloid Leukemia

Germany, Netherlands
AstraZeneca

Completed

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours (AURA2)

Non Small Cell Lung Cancer

Italy, United States, Canada, Korea, Republic of, Japan, Taiwan, Hong Kong, Spain
Ocular Therapeutix, Inc.

Active, not recruiting

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Non-proliferative Diabetic Retinopathy

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Sumitomo Pharma America, Inc.

Completed

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Recurrent Ovarian Carcinoma | Colorectal Carcinoma | EGFR Positive Non-small Cell Lung Cancer | BRAF-Mutated Melanoma

United States
Bayer

Completed

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib (ROCURS)

Coronavirus Disease 2019 (COVID-19) | SARS-CoV-2 Infection | Malignant Solid Tumors

United States
Otsuka Beijing Research Institute

Active, not recruiting

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

China
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

Glioblastoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Advanced Solid Tumors | Triple Negative Breast Cancer | Biliary Tract Cancers

United States, Argentina, Australia, Canada, Chile, Colombia, France, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, Switzerland, Taiwan, Thailand, United Kingdom

Search clinical trials for: TKI 258

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations